Phase II Study to Evaluate the Efficacy and Safety of Atezolizumab in Subjects With Unresectable or Advanced Malignant Pleural Mesothelioma Who Experienced Progression on Platinum-Based Chemotherapy
Latest Information Update: 18 May 2021
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 11 May 2021 Planned End Date changed from 1 Jun 2022 to 3 Aug 2020.
- 11 May 2021 Planned primary completion date changed from 1 Oct 2021 to 2 Aug 2020.
- 11 May 2021 Planned initiation date changed from 1 Jun 2019 to 1 Aug 2020.